scholarly journals Abdominal pain and haematochezia in a 45-year-old woman with rheumatoid arthritis receiving adalimumab treatment

2021 ◽  
Vol 14 (6) ◽  
pp. e244130
Author(s):  
Anasua Deb ◽  
Thanita Thongtan ◽  
Michael Phy ◽  
Vanessa Costilla
Keyword(s):  
Rheumatoid Arthritis ◽  
Abdominal Pain ◽  
Adalimumab Treatment

scholarly journals Seronegative Arthritis as a Complication of Whipple’s Disease

2021 ◽  
Vol 14 ◽  
pp. 117954762110177
Author(s):  
Rebecca DeBoer ◽  
Sahani Jayatilaka ◽  
Anthony Donato
Keyword(s):  
Rheumatoid Arthritis ◽  
Weight Loss ◽  
Abdominal Pain ◽  
Gastrointestinal Symptoms ◽  
Whipple’S Disease ◽  
Seronegative Arthritis ◽  
Whipple's Disease ◽  
Caucasian Male

Whipple’s disease (WD) is an uncommon cause of seronegative arthritis. WD is known for its gastrointestinal symptoms of diarrhea, weight loss, and abdominal pain. However, arthritis may precede gastrointestinal symptoms by 6 to 7 years. We describe a case of an 85-year-old Caucasian male with multiple joint complaints, not responsive to traditional treatments for conditions such as rheumatoid arthritis and osteoarthritis. We suggest that WD be considered for seronegative arthritis especially affecting large joints.

scholarly journals SAT0189 Dynamics of circulating tnf during adalimumab treatment of rheumatoid arthritis using a novel drug-tolerant tnf assay

2018 ◽  
Author(s):  
L. C. Berkhout ◽  
M. J. l'Ami ◽  
J. Ruwaard ◽  
M. H. Hart ◽  
P. Ooijevaar-de Heer ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Adalimumab Treatment ◽  
Novel Drug

scholarly journals Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study

2020 ◽  
Vol 39 (9) ◽  
pp. 2583-2592
Author(s):  
Frank Behrens ◽  
Hans-Peter Tony ◽  
Michaela Koehm ◽  
Eva C. Schwaneck ◽  
Holger Gnann ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Sick Leave ◽  
Disease Activity ◽  
Work Productivity ◽  
Work Outcomes ◽  
Work Related ◽  
Adalimumab Therapy ◽  
Adalimumab Treatment ◽  
Observational Cohort

Abstract Objective The goal of this study was to evaluate the long-term impact of adalimumab therapy on work-related outcomes in employed patients with rheumatoid arthritis (RA). Method We utilized data from an observational cohort of German patients who initiated adalimumab treatment during routine clinical care. Analyses were based on employed patients (part-time or full-time) who continued adalimumab treatment for 24 months. Major outcomes were self-reported sick leave days in the previous 6 months, absenteeism, presenteeism, and total work productivity impairment as assessed by the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity assessments. The normal number of sick leave days was based on data from the German Federal Statistical Office. Results Of 783 patients, 72.3% were women, mean age was 47.9 years, and mean disease duration was 7.8 years. At baseline (before adalimumab initiation), 42.9% of patients had higher than normal sick leave days (> 5) in the previous 6 months. During 24 months of adalimumab treatment, 61% of patients with higher than normal sick leave days at baseline returned to normal sick leave values (≤ 5 days/6 months). Overall, mean sick leave days/6 months decreased from 14.8 days at baseline to 7.4 days at month 24. Improvements were observed in WPAI assessments and disease activity measures, although presenteeism levels remained high (32.2% at month 24). Conclusions Adalimumab treatment was associated with strong and sustained improvements in work-related outcomes in employed patients who continued on adalimumab for 24 months. Presenteeism appears to be the work outcome most resistant to improvement during RA treatment. Trial registration NCT01076205 Key Points• Long-term adalimumab therapy was associated with sustained improvements in work outcomes in patients with rheumatoid arthritis.• Despite improvements in sick leave days and work absenteeism, presenteeism (impairment while at work) remained relatively high.

scholarly journals An Autopsy Case of Fulminant Amebic Colitis in a Patient with a History of Rheumatoid Arthritis

2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Naoko Kawabe ◽  
Fuyuki Sato ◽  
Miho Nagasawa ◽  
Masako Nakanishi ◽  
Yasuteru Muragaki
Keyword(s):  
Rheumatoid Arthritis ◽  
Abdominal Pain ◽  
Lung Disease ◽  
Antibacterial Agent ◽  
Full Thickness ◽  
Autopsy Case ◽  
Histochemical Analysis ◽  
Amebic Colitis ◽  
History Of ◽  
Rheumatoid Lung

Generally, amebic colitis is localized around the mucosal membrane and often accompanied by diarrhea and abdominal pain. We describe a patient with a history of rheumatoid arthritis who had received prolonged steroid therapy. The patient complained of breathing difficulties because of rheumatoid lung disease. Although the patient was given antibacterial agent, the symptoms did not improve until death. We did an autopsy and found that he had fulminant amebic colitis, although the patient was not previously examined. Histochemical analysis revealed severe inflammation and full-thickness necrosis of the colon by ameba, suggesting the involvement of ameba in the progression of the overall condition.

scholarly journals Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level

Rheumatology ◽  
2006 ◽  
Vol 45 (10) ◽  
pp. 1317-1319 ◽  
Author(s):  
A. W. A. M. van Rijthoven ◽  
J. W. J. Bijlsma ◽  
M. Canninga-van Dijk ◽  
R. H. W. M. Derksen ◽  
J. A. G. van Roon
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Antibody Level ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Dsdna Antibody ◽  
Adalimumab Treatment

Effect of the Application of Trial Inclusion Criteria on the Efficacy of Adalimumab Therapy in a Rheumatoid Arthritis Cohort

2011 ◽  
Vol 38 (9) ◽  
pp. 1884-1890 ◽  
Author(s):  
INGRID M. VISMAN ◽  
GEERTJE M. BARTELDS ◽  
WOUTER OUWERKERK ◽  
ANITA C.J. RAVELLI ◽  
LINDA M. PEELEN ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Daily Practice ◽  
Joint Disease ◽  
Inclusion Criteria ◽  
Rheumatoid Arthritis Cohort ◽  
Adalimumab Therapy ◽  
Adalimumab Treatment ◽  
Almost All ◽  
Large Prospective Cohort

Objective.To evaluate the influence of inclusion criteria used in rheumatoid arthritis (RA) trials with adalimumab on clinical outcome and response.Methods.The different inclusion criteria of published trials of adalimumab in RA were separately applied to a large prospective cohort of patients with RA treated with adalimumab (AdRA cohort), thereby mimicking patient selection for a clinical trial. Clinical response and outcome in the resulting 11 projection groups were compared using the 28-joint Disease Activity Score (DAS28) and time-averaged DAS28 as outcome measures of efficacy.Results.Thirteen trials (n = 54–799) with 11 different sets of entry criteria were identified, resulting in 11 projection groups (n = 22–168). The DAS28 at baseline was similar in the original trial and each projection group based on this trial (5.1–6.4, total AdRA cohort 5.1). After 28 weeks, the efficacy varied substantially among the 11 projected groups (change from baseline DAS28: −1.65 to −2.65, time-averaged DAS28 3.67–4.53). Expressed as outcome (DAS28 at 28 weeks), the efficacy was much more similar for almost all projection groups (3.5–4.0) and thus appeared to be mostly independent of disease activity at baseline.Conclusion.We observed that different inclusion criteria for clinical trials can have a marked effect on the expected response, i.e., improvement from baseline. A novel finding is that final disease activity appeared much less dependent on initial disease activity. Our study suggests that for daily practice, one can assume that adalimumab treatment will on average result in a DAS28 between 3.5 and 4.0 after 28 weeks of treatment, regardless of baseline disease activity.

Sign in / Sign up

Export Citation Format

Share Document